Herantis Pharma Plc Announces CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months
Data on exploratory efficacy endpoints continue to show a promising biological signal in some patientsHerantis Pharma PlcCompany release August 27, 2020 at 9:00 AM Eastern European Summer Time Herantis Pharma Plc (“Herantis” or “Company”) announced today that its novel drug candidate, Cerebral Dopamine Neurotrophic Factor (CDNF) for the treatment of Parkinson’s disease (PD), has successfully achieved its primary endpoint of safety and tolerability in a 12 month Phase I-II study in patients with moderate disease. CDNF is a multi- modal, natural protein that has shown potential to slow